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1. Introduction 
Antithrombin neutralization of thrombin activity 
involves the formation of a highly stable enzyme- 
inhibitor complex [I ,2]. The rate of this inactivation 
is markedly enhanced by the presence of heparin { 21, 
Appreciable amounts of antithrombin are also con- 
verted by thrombin to a proteolytically modified, 
noncomplexed product when the two proteins react 
in near~quimolar ratios 131, The generation of this 
modified antithrombin form is increased in the pres- 
ence of heparin (I. B. and W. W. Fish, ul~~ublished; 
K. K. Lavine and C. M. Jackson, personal communi- 
cation). The modified form of the inhibitor has a 
reduced affinity for heparin and is unable to inhibit 
thrombin [3]. 
The limited proteolysis by thrombin that produces 
the modified form of ~titilromb~ has been charac- 
terized for the bovine enzyme and inhibitor [3,4]. The 
proteolytic modification was found to be restricted 
to the scission of a single peptide bond near the 
COaH-terminus of the inhibitor, giving rise to two 
disulfide-linked fragments (Mr -50 000 and -5000). 
Since the amino acid sequence of bovine antithrombin 
is only fragmentarily known [4,5], the position of the 
cleavage site was deduced from a homology between 
the NH~-terminal sequence of the smaller fragment and 
a segment of human antithrombin starting at Ser-386 
141. The same cleaved inhibitor as that generated in 
free form is also released from the antithrombin- 
thromb~ complex by nucleop~lic agents [4,6-81 and 
dissociates pontaneously from the complex [9]. These 
find~gs have led to the conclusion that the cleavage 
site identified in bovine antithrombin is the active site 
of the inhibitor, i.e., the functional interactive site for 
protease inhibition [4,79]. 
The nearly complete amino acid sequence and the 
structure of the 4 identical oiigosac~haride chains of 
human antithrombin have recently been published 
[lO,l 11. Because of this comprehensive structural 
knowledge, and also in order to investigate the gener- 
ality of our previous findings, we have now extended 
our studies to include the reaction between human 
ar~tithrombill and human ~-thrombin. A single cleavage 
site was identified between Arg-385 and Ser-386, i.e., 
at a position homologous to that observed for the 
bovine proteins [4]. 
2. Materials and methods 
Human antithromb~ was isolated by affinity chro- 
matography on heparin-agarose f 121. Human ot- 
thrombin was prepared from fraction III paste [ 13,141 
and was crystallized from 44% saturated (NH4)aS04 
in the final preparative step (B. H. Landis and J. W. F. 
ii, unpublished). The preparation used had a specific 
clotting activity of 3300 US ‘NIH’ units/mg protein 
[13,14], was 100% active by titration withp-nitro- 
p~lenyl-~~-guanid~obeilzoate [13,1 S] and consisted 
of 92.5% cy-, 0.8% p- and 6.7% y-thrombins by SDS- 
polyacrylamide gel electrophoresis of the material 
labelled with [ “C]diisopropylphosphorofluoridate 
1141. The throlnb~-modi~ed form of human anti- 
thrombin was prepared by a modification (I. 3. and 
W. W. Fish, unpublished) of the previous method for 
the bovine protein 231. 
Sequential N&-terminal analyses were performed 
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in a Beckman 890 C sequencer with the use of poly- 
brene andaO.l MQuadrolprogram,asin [4].Phenyl- 
thiohydantoin amino acid derivatives were identified 
by high-performance liquid chromatography and thin- 
layer chromato~aphy 141. 
Table I 
Sequential NH,-terminal analysis of human modified anti- 
thrombin, compared to the reported amino acid sequence of 
the intact human protein [lo] 
3. Results and discussion 
Cycle Residues identified Known structure of intact 
human antithrombin [lo] 
at tentative postitions 
l-l 3 and 385-398 
The yield of the human modified antithrombin, 
prepared with human cr-thrombin, was -60% of that 
of the bovine modified inhibitor, prepared by the same 
method with the bovine enzyme. The isolated human 
modified antithrombin behaved identically to the 
bovine protein in SDS-polyacrylamide gel electro- 
phoresis [3]; i.e., it co-migrated with intact human 
antithrombin under non-reducing conditions but 
migrated slightly faster than the intact protein under 
reducing conditions. The difference in mobility corre- 
sponded to an N, difference of -5000. Urea-poly- 
acrylamide gel electrophoresis [3] of the reduced and 
alkylated human protein showed the presence of a 
small peptide with the same mobility as the peptide 
derived from modified bovine antithromb~ [3]. These 
results clearly indicate that the limited proteolytic 
cleavage ofhuman antithrombin by human a-thrombin 
is analogous to that previously reported for the bovine 
system. 
385 Arg 
1 His(H) Ser(H,T) 1 His Ser 
2 Gly(H,T) Leu(H,T;38) GlY Leu 
3 Ser(H,T) Asn(H,T) Set Asn 
4 Pro(II,T;68) Pro Pro 
5 Val(H,T;37) Asn(H,T) 5 Val 390 Asn 
6 Asp(H,T) A@0 ASP A% 
I Ile(H,T;34) Val(H,T;39) Ile Val 
8 (CY s)(T) Thr(H,T) CYS Tht 
9 Thr(H ,T) Phe(H,T;27) Thr Phe 
10 Ala(H,T;29) Lys(H,T) 10 Ala 395 LYS 
11 Lys(H,T) Ala(H,T;28) LYS Ala 
12 Pro(H) Asn(H,T) Pro Am 
13 (AMII) AS Afg 
Letters in parentheses indicate methods for identification of 
phenylthiohydantoin derivatives: H, high-performance liquid 
chromatographY;T,th~-dyer chromato~aphy.~~umbersgive 
nmol derivatives recovered in cycles where quantitation was 
reliable. About 65 nmoi protein were analysed 
The thrombin cleavage site in human antithrombin 
was identified by direct NHz-terminal sequence anal- 
ysis of the isolated modified protein without reduc- 
tion or separation of its fragments. About 65 nmol of 
protein were analysed; the initial coupling was -70% 
and the repetitive yield -94%. In each cycle, two 
phenylthioIlydantoin amino acid derivatives were 
recovered in essentially equal amounts,except in cycles 
4 and 13, where single derivatives were obtained in 
about double the normal yield (table 1). Additional 
derivatives were not detected in any cycle, indicative 
of only a single proteolytic cleavage. Comparison with 
the nearly complete sequence of human antithrombin 
[lo] established that the residues identified corre- 
spond to those of the NH~-terminal sequences of the 
intact protein and of a fragment of this protein result- 
ing from the cleavage between Arg-385 and Ser-386. 
Cleavage at this site produces an NHz-terminal frag- 
ment comprising -385 residues and a 39-residue 
COzH-terminal fragment, which are joined by a single 
disulfide bridge (fig.1). 
antithrombin is thus in a position homologous to that 
shown 147 for the cleavage of the bovine inhibitor by 
the bovine enzyme. This homology provides addition- 
al, strong evidence that the observed cleavage site is 
the active site of the inhibitor; i.e ., the functional 
interactive site for protease inhibition [4,7,9]. The 
proposed location of this site is supported by demon- 
strations of a homologous active site in the COzH-ter- 
minal region of human cur-protease inhibitor [16,17]. 
In our studies with bovine antithrombin, the liber- 
ation of arginine as the COzH-terminal residue of the 
larger fragment of the modified inhibitor could only 
be inferred from sequence honlology with human anti- 
thrombin [4]. The present identification of the 
Arg-385/Ser-386 cleavage site within the reported 
amino acid sequence of the human inhibitor [ 101 
clearly establishes the participation of an arginine at 
the thrombin-interactive site. This is in agreement with 
earlier chemical modification studies [2] and with the 
recent demonstration of the release of an arginine by 
carboxypeptidase B digestion of antithrombin-throm- 
bin complex which had been dissociated with methoxy- 
amine hydrochloride [ 81. 
The site at which human cu-thrombin cleaves human Immediately preceeding Arg385 in human anti- 
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Fig.1. The position of the identified t~lrornb~ cleavage site within human antit~omb~. The gross polypeptide structure, assigned 
disulfide bridges (S-S-) and carbohydrate attachment sites (CHO) are from [ IO]. The sequence surrounding the thrombin cleavage 
site is shown, and the hydrophobic residues of the hexapeptide preceeding the cleavage site are underlined. 
thrombin is a unique hydrophobic hexapeptide 
(Ala-379 through Gly-384; fig.1). This hydrophobic 
peptide may be of functional importance in that it 
may contribute stab~~ty to the antithrombin-throm- 
bin complex by apolar associations with complemen- 
tary hydrophobic sites in thrombin. A variety of evi- 
dence strongly suggests that such sites (e.g., for indole 
or proflavine binding and for boding of hydrophobiG 
residues preceeding the arginine in synthetic tripeptide 
substrates) are situated near the catalytic site in throm- 
bin and most likely correspond to the NHz-terminal 
side of a thronlb~-susceptible bond [ 18,191. These 
sites exist both in ar-thrombin with high clotting activ- 
ity and in nonclotting, autoproteolytically derived p- 
and y-thrombins [20-221. This is in contrast to certain 
active-site regions for fibrinogen recognition, which 
are found only in procoagulant cu-thrombin [20]. The 
conservation of such hydrophobic sites in the 3 throm- 
bin forms may explain why antithrombin reacts simi- 
larly with all these forms [20,2 I]_ Moreover, the accel- 
erating effect of heparin on the antithromb~-throm- 
bin reaction may involve a conformational change of 
antithromb~ [2,23,24], by which the hydrophobic 
peptide and the contiguous Arg-385/Ser-386 bond 
become more accessibk for interaction with thrombin. 
In support of this hypothesis, factor X, does not share 
with thrombin the same affinity for hydrophobic resi- 
dues preceeding arginine in synthetic substrates [19,221 
and does not react as rapidly as thrombin with anti- 
thrombin in the presence of heparin [25]. 
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